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ABSTRACT  57 
Hodgkin lymphoma (HL) is characterized by an extensively dominant tumor 58 
microenvironment (TME) composed of different types of non-cancerous immune cells 59 
with rare malignant cells. Characterization of the cellular components and their spatial 60 
relationship is crucial to understanding crosstalk and therapeutic targeting in the TME. 61 
We performed single-cell RNA sequencing of more than 127,000 cells from 22 HL 62 
tissue specimens and 5 reactive lymph nodes, profiling for the first time the phenotype 63 
of the HL-specific immune microenvironment at single-cell resolution. Single-cell 64 
expression profiling identified a novel HL-associated subset of T cells with prominent 65 
expression of the inhibitory receptor LAG3, and functional analyses established this 66 
LAG3
+ 
T cell population as a mediator of immunosuppression. Multiplexed spatial 67 
assessment of immune cells in the microenvironment also revealed increased LAG3
+ 
T 68 
cells in the direct vicinity of MHC class-II deficient tumor cells. Our findings provide 69 
novel insights into TME biology and suggest new approaches to immune checkpoint 70 
targeting in HL.  71 
 72 
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STATEMENT OF SIGNIFICANCE  74 
We provide detailed functional and spatial characteristics of immune cells in cHL at 75 
single cell resolution. Specifically, we identified a Treg-like immunosuppressive subset 76 
of LAG3
+
 T cells contributing to the immune escape phenotype. Our insights aid in the 77 
development of novel biomarkers and combination treatment strategies targeting 78 














on January 15, 2020. © 2019 American Association forcancerdiscovery.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on December 19, 2019; DOI: 10.1158/2159-8290.CD-19-0680 
5 
 
INTRODUCTION  92 
Classic Hodgkin lymphoma (cHL) is the most common lymphoma subtype 93 
among adolescents and young adults(1). cHL is characterized by an extensive 94 
microenvironment composed of different types of non-cancerous normal immune cells, 95 
such as several types of T cells, B cells, eosinophils and macrophages, and a rare 96 
population (~1%) of clonal malignant Hodgkin and Reed-Sternberg (HRS) cells(1-3). 97 
While some findings support the concept that the HRS cells recruit these immune cells 98 
to form a tumor-supporting, regulatory tumor microenvironment (TME) with limited 99 
anti-tumor activity in cHL(4-6), the complex interactions between HRS cells and their 100 
TME remain only partially understood. A deeper understanding of this symbiotic 101 
cellular crosstalk (‘ecosystem’) may lead to the development of novel biomarkers and 102 
therapeutic approaches. 103 
Immune checkpoint inhibitors, such as the programmed death 1 (PD-1) 104 
inhibitors nivolumab and pembrolizumab, have shown dramatic efficacy in relapsed or 105 
refractory cHL with an overall response rate (ORR) of 65-87%(7,8), and durable 106 
remissions of approximately 1.5 years(8), which compares very favorably to other 107 
agents in this setting(9). Although the emergence of novel drugs emphasizes the need 108 
for the identification of predictive biomarkers that can provide a rationale for treatment 109 
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selection, it remains unclear which cells are the most important targets of immune 110 
checkpoint inhibitors and which components are most relevant for the immune escape 111 
phenotype in cHL. Thus, further comprehensive investigations of this interaction are 112 
needed. 113 
Previous studies have applied immunohistochemistry (IHC), microarray, 114 
cytometry by time-of-flight (CyTOF) and NanoString assays to characterize the 115 
immune phenotype of the TME in cHL, and have identified some important associations 116 
between the presence of certain immune cell types and clinical outcome(4,6,10). 117 
Although previous reports have described enrichment of CD4
+
 T cells in the TME of 118 
cHL(10-12), their study scale has been limited and detailed co-expression patterns of 119 
important markers such as inhibitory receptors have not been examined.  120 
Recently, the landscape of tumor infiltrating T cells has been assessed using 121 
single-cell transcriptome sequencing in several solid tumors, mostly of epithelial 122 
origin(13,14). These single-cell RNA sequencing (scRNA-seq) studies have revealed 123 
diverse immune phenotypes, such as cells exhibiting an exhaustion signature, as well as 124 
clonal expansion patterns of T cell lineages(14). However, such analyses are currently 125 
lacking in lymphomas, which differ from most solid cancers in that they are clonally 126 
derived from lymphocytes that professionally interact with other immune cells in the 127 
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ecosystem of the microenvironment. 128 
In this study, we performed high dimensional and spatial profiling of immune 129 
cells in cHL using scRNA-seq of 127,786 cells, multicolor IHC and imaging mass 130 
cytometry (IMC). We identified unique regulatory T cell-like subset that expressed 131 
lymphocyte activation gene 3 (LAG3
+
 T cells) in cHL and were mostly absent in normal 132 
reactive lymph nodes. LAG3
+
 T cells were characterized by expression of 133 
interleukin-10 (IL-10) and transforming growth factor  (TGF-, and we demonstrated 134 
an immuno-suppressive function of these cells. Further topological analysis revealed 135 
that HRS cells were closely surrounded by frequent LAG3
+
 T cells in the subset of cHL 136 
patients with loss of Major histocompatibility class II (MHC-II) expression on tumor 137 
cells. Our data provide an unprecedented number of single-cell transcriptomes in 138 
combination with multiplexed spatial assessment, allowing us to decipher the unique 139 
immune cell architecture of the TME in cHL with implications for novel therapies, 140 
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The cHL-specific immune microenvironment at single-cell resolution 146 
To characterize the transcriptional profile of immune cells in the TME of cHL, 147 
we performed scRNA-seq on single cell suspensions collected from lymph nodes of 22 148 
cHL patients, including 12 of nodular sclerosis (NS) subtype, 9 of mixed cellularity 149 
(MC) subtype, and 1 of lymphocyte-rich (LR) subtype. We also sequenced reactive 150 
lymph nodes (RLN; n = 5) from healthy donors as normal controls (Supplementary 151 
Tables 1 and 2). Transcriptome data were obtained for a total of 127,786 sorted live 152 
cells, with a median of 1,203 genes detected per cell (Supplementary Table 3). To 153 
perform a systematic comparative analysis of the cHL TME and RLN, we merged the 154 
expression data from all cells (cHL and RLN) and performed batch correction and 155 
normalization. Removal of batch effects (caused by single cell isolation and library 156 
preparation in different experimental runs) resulted in improved mixing of cells across 157 
samples, as demonstrated by a significant increase in cell entropy 158 
(Wilcoxon-Mann-Whitney p < 0.001; Supplementary Fig. 1A-B). 159 
Unsupervised clustering using PhenoGraph followed by visualization in t-SNE 160 
space(15,16) identified 22 expression-based cell clusters that were annotated and 161 
assigned to a cell type based on the expression of genes described in published 162 
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transcriptome data of sorted immune cells(17) and known canonical markers (Fig. 1A; 163 
Supplementary Fig. 2A-E and 3). These included 4 naïve T cell clusters, 2 CD8
+
 T 164 
cell clusters, 6 CD4
+
 T cell clusters, 7 B cell clusters, 1 macrophage cluster, 1 165 
plasmacytoid dendric cell cluster and 1 progenitor cell cluster. We coud not observe 166 
HRS cell cluster may be due to limitation of microfluidics approach. While most 167 
immune cell phenotypes exhibited overlap between cHL and RLN as demonstrated by 168 
clusters containing a mixture of cell types, we observed an enrichment of cells from 169 
cHL in some specific cell clusters (Fig. 1B). Of interest, we found that all three 170 
regulatory T cell (Treg) clusters were quantitatively dominated by cells derived from the 171 
cHL samples with only a minor proportion originating from RLNs (Fig. 1C), and that 172 
the proportion of cells assigned to Treg clusters was significantly higher in cHL samples 173 
compared to RLN (P = 0.0001; t-test; Fig. 1D). The cluster containing the highest 174 
proportion of immune cells from cHL samples (“CD4-C5-Treg”) also exhibited 175 
relatively high expression of LAG3 and CTLA4 (Fig. 1A). Conversely, clusters 176 
enriched in RLN were mostly B cell and CD8
+
 T cell clusters (Fig. 1C). Further 177 
examination of the non-Treg CD4
+
 T cell clusters revealed that they were primarily 178 
composed of type 2 T helper (Th2) cells, and that Th1 and Type 17 T helper (Th17) 179 
cells were also enriched in cHL samples compared to RLN (Fig. 1E). We also 180 
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performed differential expression analysis between cHL and RLN cells within each 181 
cluster, and identified IL-32 as consistently upregulated in cHL T cells compared to 182 
RLN T cells (Supplementary Fig. 4). IL-32 is a known pro-inflammatory cytokine that 183 
can induce the production of other cytokines such as IL-6(18). 184 
 185 
EBV status affects the immune cell subset composition in cHL  186 
Thirty to 40% of cHL are associated with latent Epstein-Barr virus (EBV) 187 
infection of the malignant HRS cells(19), and several reports indicate that EBV 188 
infection can recruit specific Treg populations to the TME in cHL(20,21). To more 189 
precisely define immune cell composition according to EBV status, we compared the 190 
RNA-seq data of 5 EBV
+
 vs 17 EBV
-
 cases (Supplementary Fig. 5A). The proportion 191 
of CD4
+
 T cells with a Th17 profile was significantly decreased in EBV
+
 cHL (P = 192 





 cases with respect to CD8
+
 T cell or Treg proportions (Fig. 1F; 194 
Supplementary Fig. 5B). Similarly, the cHL mixed cellularity (MC) subtype, which is 195 
more commonly associated with EBV related cHL, was associated with a lower 196 
proportion of Th17 polarized immune cells as compared to the nodular sclerosis (NS) 197 
subtype (Fig. 1H; Supplementary Fig. 5C).  198 
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Single cell expression patterns of novel cHL-specific immune subsets 200 
Our data demonstrated the preferential enrichment of Tregs in cHL as compared 201 
to RLN (Fig. 1B and D). Considering the importance of an immuno-suppressive 202 
microenvironment as a cancer hallmark, and its implications for biomarker development 203 
and targeted immunotherapy, we focused our analyses on the detailed characterization 204 
of Treg subsets. The most cHL-enriched Treg cluster, CD4-C5-Treg (Fig. 1A), was 205 
characterized by high expression of LAG3 in addition to common Treg markers such as 206 
IL2RA (CD25) and TNFRSF18 (GITR) (Fig. 2A). However, other canonical Treg 207 
markers such as FOXP3 were not co-expressed in this cluster, suggesting these cells 208 
may exhibit a type 1 regulatory (Tr1) T cell phenotype(20,22) (Fig. 2B; 209 
Supplementary Fig. 6A). To confirm the expression pattern of immune cells in cHL, 210 
we also assessed the expression of surface and intracellular markers in all cHL cases 211 
using multi-color IHC and IMC. The orthogonal data confirmed the inversely correlated 212 
expression pattern of LAG3 and FOXP3 on CD4
+
 T cells at the protein level 213 
(Supplementary Fig. 6B-C). 214 
Inhibitory receptor-mediated immune tolerance that can be hijacked by tumors 215 
has been a major target of cancer immunotherapy(23,24). To gain more insight into the 216 
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characteristics of inhibitory receptor expression in the TME of cHL, we explored 217 
expression patterns among individual T cells. While LAG3-expressing cells were 218 
mostly assigned to Treg clusters, PD-1-expressing cells were primarily assigned to 219 
non-Treg CD4
+
 T cell clusters (Fig. 2C). Interestingly, CD8
+
 T cells, including CTLs, 220 
are not the dominant population expressing PD-1 and LAG3 (Fig. 2C-D), indicating the 221 
importance of the CD4
+
 T cell population for immune checkpoint regulation in cHL. 222 
Notably, the expression pattern of inhibitory receptors was variable among T cell 223 
subsets (Fig. 2E), suggesting a specific role of each inhibitory receptor in each T cell 224 
subset in cHL. Analyzing co-expression patterns on the single cell level revealed that 225 
the majority of LAG3
+ 
T cells co-expressed CTLA4 which is known as more universal 226 
Treg marker, but not PD-1 (Fig. 2F). Similarly, most PD-1
+
 T cells did not co-express 227 
LAG3. CTLA-4 was also co-expressed by FOXP3
+
 T cells (Supplementary Fig. 6A). 228 
These co-expression patterns were validated using FCM (Supplementary Fig. 7A-B). 229 
Interestingly, LAG3, TIGIT and PD-1 were not co-expressed by the majority of CD8
+
 T 230 
cells. Furthermore, although we observed a trend towards higher proportions of 231 




 T cells in RLN samples, the proportion of 232 
LAG3
+





T cells in cHL pathogenesis (Supplementary Fig. 7C).  234 
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To explore the functional role of LAG3
+
 T cells, we next applied the diffusion 235 
map algorithm(25,26) with the aim of characterizing differentiation states among CD4
+
 236 
T cells (Fig. 2G). Most T cells were grouped by PhenoGraph cluster, and the first 237 
dimension showed a trajectory beginning with naïve T cells and ending with Tregs. 238 
LAG3
+ 
T cells were enriched at the far end of this dimension, which was correlated with 239 
genes representative of a terminal differentiation signature (Methods; Supplementary 240 
Fig. 8A). Consistent with a previous report that showed LAG3
+
 T cells confer 241 
suppressive activity through their significantly reduced proliferation activity(27), 242 
LAG3
+
 T cells were also located in the middle to negative end of the second dimension, 243 
which correlated with G2/M cell cycle and glycolysis signature genes (Supplementary 244 
Fig. 8B). Furthermore, the most positively correlated genes with dimension 1 were 245 
LAG3, LGMN and CTLA4, which are known markers of suppressive function in Tregs, 246 
indicating the suppressive signature of LAG3 in these T cells (Supplementary Fig. 247 
8C-D). 248 
 249 
cHL cell line supernatant can induce LAG3
+ 
T cells 250 
To characterize the immunosuppressive signature of Tregs in cHL, we 251 
investigated the cytokine expression of LAG3
+
 T cells. Among the CD4
+
 cluster T cells, 252 
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 T cells had higher expression of immune-suppressive cytokines IL-10, TGF- 253 
and IFN- compared to LAG3
-
 T cells (Fig. 3A). These characteristics are consistent 254 
with the profile of type 1 regulatory T cells(28,29). 255 
Taken together, our data consistently demonstrate a suppressive phenotype of 256 
LAG3
+
 T cells in cHL. We hypothesized that cytokines or chemokines produced by 257 
HRS cells might influence the TME in cHL. Thus, we next assessed the effect of 258 
supernatant transfer of various lymphoma cell lines on the expansion of T cells in vitro. 259 





 T cells co-cultured with cHL cell line supernatant expressed significantly higher 261 
levels of LAG3 as compared to those co-cultured with diffuse large B-cell lymphoma 262 
(DLBCL) cell line supernatant or medium only (Fig. 3B-C). Luminex analysis revealed 263 
that the presence of cHL cell line supernatant resulted in enrichment of multiple 264 
cytokines and chemokines as compared to DLBCL cell lines, including TARC/CCL17, 265 
TGF-, and IL-6, which are known enhancers of Treg migration and 266 




 T 267 









 T cells 269 
suppressed the proliferation of responder CD4
+
 T cells when co-cultured in vitro, 270 
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confirming an immunosuppressive function of the LAG3
+
 T cells (Fig. 3F).  271 
 272 
Spatial assessment of LAG3
+
 T cells and HRS cells 273 
We next sought to understand the spatial relationship between LAG3
+ 
T cells 274 
and malignant HRS cells. IHC of all cases revealed that LAG3
+ 
T cells were enriched in 275 
the cHL TME compared to RLN, and in a subset of cHL cases HRS cells were closely 276 
surrounded by LAG3
+
 T cells (Fig. 4A). Of note, our single cell analysis revealed that 277 
LAG3 expression was significantly higher in cases with MHC class II negative HRS 278 
cells (n = 6) as compared to those with MHC class II positive cHL cases (n = 16), but 279 
was not correlated with EBV status or histological subtype (Fig. 4B; Supplementary 280 
Fig. 9A-C). Strikingly, when examining cells within the CD4-C5-Treg cluster, LAG3 281 
was identified as the most up-regulated gene in MHC class II negative cells compared 282 
to MHC class II positive cells (Fig. 4C). Characterization of immune markers using 283 
IHC showed not only a marked increase in LAG3
+
 T cells, but also a decrease in 284 
FOXP3
+
 T cells in MHC-II negative cases when compared to MHC-II positive cases 285 




 T cells by 286 
MHC-II status, suggesting the LAG3
+
 cells represent a distinct sub-population of the 287 
HL-specific CTLA4
+
 cells previously reported(12) (Supplementary Figure 9D). To 288 
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 T cells using multicolor IHC (Fig. 4E-G). We confirmed that the density 290 
of LAG3
+
 T cells in HRS-surrounding regions was significantly increased in MHC class 291 
II negative cases, but not correlated with either MHC class I status, pathological subtype 292 
or EBV status (Fig. 4E; Supplementary Fig. 10A). Similarly, the average nearest 293 
neighbor distance between CD30
+
 cells (HRS cells) and their closest LAG3
+
 T cell was 294 
significantly shorter in MHC class II negative cHL cases (Fig. 4F). In contrast, the 295 
density of HRS-surrounding FOXP3
+ 
T cells was higher in cases with MHC class II 296 
positive HRS cells (Fig. 4E; Supplementary Fig. 10B), and the nearest neighbor 297 
distance from HRS cells to FOXP3
+
 cells was also shorter in these cases (Fig. 4F; 298 
Supplementary Fig. 11A-B). 299 
To further investigate the spatial relationship between HRS cells and their 300 
surrounding cells, we next assessed the expression of surface and intracellular markers 301 
in all cHL study cases using IMC, which allows for simultaneous interrogation and 302 
visualization of 35 protein markers in the spatial context of the TME. Consistent with 303 









 cells (Fig. 5A; Supplementary Fig. 12A). 305 




 T cells and abundant 306 
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 T cells rosetting the HRS cells. We also confirmed the observed 307 
significantly shorter nearest neighbor distances between HRS cells and their closest 308 
LAG3
+
 T cell in MHC class II negative cHL cases when compared to MHC class II 309 
positive cHL cases using IMC data (Supplementary Fig. 12B-C).  310 
 311 
The number of LAG3
+ 
T cells in the tumor microenvironment is correlated with 312 
loss of MHC-II expression in a large validation cohort 313 
We next validated our findings using IHC of an independent cohort of 166 314 
patients uniformly treated with first-line ABVD (doxorubicin, bleomycin, vinblastine 315 
and dacarbazine) as described in Steidl et al(6) and investigated the potential prognostic 316 
value of the presence of LAG3
+
 T cells. Consistent with the results from scRNA-seq, 317 
we found that the proportion of LAG3
+
 T cells present in tumor tissue was significantly 318 
higher in cases with MHC class II negative HRS cells as compared to those with MHC 319 
class II positive HRS cells, but was not associated with EBV status (Fig. 5B-C). In 320 
addition, we observed a trend towards shortened disease-specific survival (DSS; P = 321 
0.072) and overall survival (OS; P = 0.12) in patients with an increased number of 322 
LAG3
+
 T cells (Supplementary Fig. 13A-B). Of note, a high proportion of LAG3
+
 T 323 
cells (> 15%) and CD68
+
 tumor-associated macrophages (≥ 5%)(6) were identified as 324 
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independent prognostic factors for DSS by multivariate Cox regression analysis (also 325 
considering MHC II expression and International Prognostic Score (IPS) as variables; 326 
(Supplementary Fig. 13C). In the absence of statistically significant outcome 327 
correlates in the present cohorts of pretreatment HL samples, we examined an 328 
independent cohort of patients with relapsed cHL uniformly treated with high dose 329 
chemotherapy followed by autologous stem cell transplantation (ASCT)(4). We 330 
similarly found that abundant LAG3
+
 T cells were associated with unfavorable 331 
post-ASCT survival, although statistical significance was not reached, likely due to 332 
sample size (Supplementary Fig. 13D).  333 
 334 
Cross-talk between HRS cells and LAG3
+
 T cells in cHL 335 
To investigate the role of HRS cells in their interaction with the cHL 336 
microenvironment, we next explored Affymetrix gene expression data generated from 337 
micro-dissected HRS cells of primary HL samples(39) (see Supplementary Methods 338 
for details). We validated the high expression level of the cytokines and chemokines 339 
that we observed in the in vitro Luminex assay (Fig. 6A. Notably, IL-6, which is a 340 
known promoter of Tr1 cell differentiation(38), was the only cytokine that showed 341 
significantly higher expression in MHC-II negative HRS cells compared to MHC-II 342 
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 T cells were also induced by IL-6 in vitro (Fig. 6B), 343 




 T cells in cHL. 344 
MHC-II is also a known LAG-3 ligand(40,41). To investigate the interaction 345 
between LAG3
+
 T cells and MHC-II on HRS cells, we generated CIITA knockouts in 346 
the L-428 cHL cell line, as CIITA is the master regulator of MHC-II expression, and 347 
confirmed the MHC-II negative status of these CIITA knockout cells (Supplementary 348 
Fig. 14A). Next, we isolated LAG3
+
 T cells induced from PBMC using L-428 349 
supernatant transfer. In co-culture of these LAG3
+
 T cells with either CIITA wild-type 350 
or knockout L-428 cells, we observed that LAG-3 expression was significantly 351 
decreased with MHC-II positive L-428, suggesting negative regulation of LAG3
+
 T cell 352 
function through a direct MHC-II-LAG3 interaction (Fig. 6C). We also evaluated 353 
expression of cytokines, including IL-6 and TARC, from both CIITA wild-type and 354 
knockout L-428 cells, and observed no significant difference (Supplementary Fig. 355 
14B). Taken together, these findings suggest that while IL-6 induces LAG3
+
 T cells, 356 
MHC-II positivity actively depletes them, thus a mechanism for induction and 357 
persistence is present only in MHC-II negative tumors. We also investigated the 358 
expression of other LAG3 ligands on HRS cells according to MHC-II status in the 359 
Affymetrix dataset, and found that their expression was not significantly increased 360 
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relative to normal GCB cells (Supplementary Fig. 14C). In addition, there was no 361 
correlation between the expression level of LAG3 ligands according to MHC-II status, 362 
suggesting no direct interaction with these ligands in cHL. 363 
 364 
T cells from cHL clinical samples are activated after removal of LAG3
+
 T cells 365 
To confirm the pathogenic role of LAG3
+







 T cells and remaining T cells from cell suspensions of 367 
4 patients. We then co-cultured
 






 T cells in 368 
vitro, and observed that proliferation was suppressed in the T cells co-cultured with the 369 
LAG3
+
 population, while proliferation and expression of the intracellular cytokine, 370 
TNF, were significantly increased in the population cultured without LAG3
+
 cells (Fig. 371 





 T cells in cHL clinical samples, providing preclinical rationale for 373 
targeting LAG3
+
 T cells and their interactions to promote reactivation of T cells in a 374 
subset of patients.  375 
Our results suggest a model in which the immunosuppressive 376 
microenvironment of MHC class II negative HRS cells (Type 1) is highly organized and 377 




T cells, which in turn are induced by cytokines and 378 
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chemokines produced by HRS cells (Fig. 7). Aggregating all of these results, we reason 379 
that cross-talk between LAG3
+
 T cells and HRS cells may be an essential mechanism of 380 
immune escape in cHL, with potential implications for outcome prediction of 381 




Using scRNA-seq and IMC at an unprecedented scale, we comprehensively 386 
characterized immune cell populations to generate an immune cell atlas of the TME in 387 
classic Hodgkin lymphoma at both the RNA and protein level. In addition to 388 
reproducing known TME characteristics in cHL at single cell resolution, such as a 389 
Treg/Th2-rich environment(10,11), a Th17-predominant profile in EBV
+





 T cell population(12), we also identified and characterized in detail 391 
novel cellular subpopulations, including immuno-suppressive LAG3
+ 
T cells(40) that 392 
are linked to unique pathologic and clinical parameters. Strikingly, Treg populations 393 
and the LAG3
+ 
T cell population in particular emerged as the most highly enriched and 394 
cHL-characteristic cellular component. 395 
  LAG3 is a selective marker of type 1 T regulatory (Tr1) cells, which in contrast to 396 
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natural Tregs derived from the thymus, are known as induced Tregs that exhibit strong 397 
immunosuppressive activity(20-22,27). Consistent with characteristics of Tr1 cells, the 398 
expression of the suppressive cytokines IL-10 and TGF-(22,27), was very high in 399 
LAG3
+
 T cells, whereas FOXP3 was not co-expressed in LAG3
+
 T cells in our 400 
scRNA-seq and IMC data. Furthermore, LAG3
+
 T cells demonstrated substantial 401 
suppressive activity in vitro, indicating an immunosuppressive role of these cells in the 402 
TME of cHL. 403 
Unlike previous reports that found EBV infection increased Tr1-related gene 404 
expression including LAG3 in cHL(20), we identified a significant LAG3
+
 Treg 405 
population regardless of EBV status by scRNA-seq, multi-color IHC, IMC, and single 406 





 T cells were enriched in cases with MHC class II negative HRS cells. 408 
Interestingly, MHC class II deficiency was reported as a predictor of unfavorable 409 
outcome after PD-1 blockade(43). Our scRNA-seq data revealed that each T cell subset 410 
had a specific expression pattern of inhibitory receptors including PD-1 and LAG3. 411 




 T cells did not co-express PD-1, and the 412 
absence of PD-1 has been reported to represent functionally active Tregs in solid 413 
cancer(44), indicating the potential of LAG3 as a separate and complementary 414 
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immunotherapeutic target in cHL. The FOXP3
+
 Tregs that are enriched in MHC-II 415 
positive HRS cells in this study might be similar to the PD-1 negative FOXP3
+
 Tregs 416 
previously reported(10). 417 
MHC class II is one of the major ligands of LAG3(40,41) and we showed 418 
negative regulation of LAG3
+
 T cell expression through MHC-II and LAG3 interaction 419 





 T cells were preferentially observed surrounding MHC class II 421 
negative HRS cells. Additionally, our in vitro co-culture findings suggest that cytokines 422 




 T 423 
cells in the TME. In particular, re-analysis of expression on laser micro-dissected HRS 424 
cells revealed that MHC-II negative HRS cells had higher levels of IL-6, a cytokine 425 
known to induce Tr1 cells(38). Alternative ligands of LAG3 that mediate the immune 426 
suppressive function(45,46) might contribute to these interactions, although we did not 427 
observe any differences in their expression on HRS cells according to MHC-II status.  428 
Our findings suggest that LAG3
+
 T cells induced by cytokines and chemokines 429 
from HRS cells play an important role in substantial immunosuppressive activity in the 430 
TME of cHL. Importantly, LAG3 is a cancer immuno-therapeutic target in ongoing 431 
clinical trials in malignant lymphoma, including cHL (NCI trial ID 02061761), and we 432 
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showed the potential of removing the LAG3
+
 population as a means of reactivating T 433 
cell activity. While currently our data do not demonstrate value of LAG3
+
 T cells as a 434 
prognostic biomarker, and pending further studies in additional cohorts, it will be 435 
critical to evaluate the potential of LAG3
+
 T cells as a predictive biomarker in the 436 
context of treatments targeting LAG3
+
 T cells and their cellular interactions. In 437 
particular, ongoing trials of LAG3-targeting antibodies and antibody-drug conjugates 438 
against CTLA-4 or CD25 (which would target LAG3
+
 cells among others) will allow 439 
this evaluation. Moreover, additional investigations into the biology of immune cell 440 
interactions, including LAG3
+
 T cells and other immune cell types, may be beneficial 441 
for future therapeutic development of alternative checkpoint inhibitors. 442 
In conclusion, our comprehensive analysis provides, for the first time, detailed 443 
functional and spatial characteristics of immune cells in the cHL microenvironment at 444 
single cell resolution. We identified unique expression signatures of TME cells, 445 
including LAG3
+
 T cells, and our findings provide novel insights and texture to the 446 
central hypothesis of CD4
+
 T cell mediated immune-suppressive activity in the 447 
pathogenesis of cHL. Importantly, our findings will facilitate a deeper understanding of 448 
the mechanisms underlying the immune escape phenotype in cHL, and aid in the 449 
development of novel biomarkers and treatment strategies.  450 
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Detailed materials and methods are available in the Supplementary Data file. 452 
 453 
Tissue samples 454 
For single cell RNA sequencing, a total of 22 patients with histologically confirmed 455 
diagnostic (n = 21) or relapsed (n = 1) classic Hodgkin Lymphoma (cHL) and reactive 456 
lymphoid hyperplasia (but no evidence of malignant disease or systemic autoimmune 457 
disease) (n = 5) were included in this study. Patients were selected based on the 458 
availability of tissue that had been mechanically dissociated and cryopreserved as cell 459 
suspensions following diagnostic lymph node biopsy from British Columbia (BC) 460 
Cancer. Patient characteristics are summarized in Supplementary Table 1 and 2.  461 
The independent validation cohort consisted of 166 cHL patients uniformly treated 462 
with ABVD at BC Cancer between 1994 and 2007 from the cohort described in Steidl et 463 
al(6). This cohort was derived from a population-based registry (Centre for Lymphoid 464 
Cancer database, BC Cancer Agency), enriched for treatment failure. The median 465 
follow-up time for living patients was 4.1 years (range: 0.5 to 24.4 years). The relapse 466 
cohort consisted of 55 relapsed or refractory cHL patients uniformly treated with high 467 
dose chemotherapy and ASCT at BC Cancer, from the cohort described in Chan et 468 
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This study was reviewed and approved by the University of British Columbia-BC 470 
Cancer Agency Research Ethics Board (H14-02304), in accordance with the 471 
Declaration of Helsinki. We obtained written informed consent from the patients or the 472 
need for consent was waived in the retrospective study.  473 
 474 
Single cell RNA sequencing sample preparation  475 
To identify live cells, we used DAPI (Sigma-Aldrich, St. Louis, MO) for live-dead 476 
discrimination. Cell suspensions from cHL tumors or reactive lymph node were rapidly 477 
defrosted at 37
o
C, washed in 10ml of RPMI1640/10% fetal bovine serum (FBS) 478 
solution or RPMI1640/20% FBS solution containing DNase I (Millipore Sigma, 479 
Darmstadt, Germany) and washed in PBS. Cells were resuspended in PBC containing 480 
3% FBS and stained with DAPI for 15 min at 4C in the dark. Viable cells (DAPI 481 
negative) were sorted on a FACS ARIAIII or FACS Fusion (BD Biosciences) using an 482 
85 µm nozzle (Supplementary Fig. 16). Sorted cells were collected in 0.5 ml of 483 
medium, centrifuged and diluted in 1x PBS with 0.04% bovine serum albumin (BSA). 484 
Cell number was determined using a Countess II Automated Cell Counter whenever 485 
possible. 486 
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Library Preparation and single-cell RNA sequencing 488 
In total, 8,600 cells per sample were loaded into a Chromium Single Cell 3’ Chip kit v2 489 
(PN-120236) and processed according to the Chromium Single Cell 3’ Reagent kit v2 490 
User Guide. Libraries were constructed using the Single 3’ Library and Gel Bead Kit v2 491 
(PN-120237) and Chromium i7 Mulitiplex Kit v2 (PN-120236). Single cell libraries 492 
from two samples were pooled and sequenced on one HiSeq 2500 125 base PET lane. 493 
CellRanger software (v2.1.0; 10X Genomics) was used to demultiplex the raw data, 494 
generate quality metrics, and generate per-gene count data for each cell. 495 
 496 
Normalization and batch correction 497 
Analysis and visualization of scRNA-seq data was performed in the R statistical 498 
environment (v3.5.0). CellRanger count data from all cells (n = 131,151) were read into 499 
a single ‘SingleCellExperiment’ object. Cells were filtered if they had ≥ 20% reads 500 
aligning to mitochondrial genes, or if their total number of detected genes was ≥ 3 501 
median absolute deviations from the sample median. This yielded a total of 127,786 502 
cells for analysis. The scran package (v1.9.11) was used to quick cluster the cells and 503 
compute cell-specific sum factors with the method described by Lun et al(47). (see 504 
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Supplementary Methods for details). The scater package (v1.8.0) was used to 505 
log-normalize the count data using the cell-specific sum factors. 506 
To remove batch effects resulting from different chips and library preparation, 507 
the fast mutual nearest neighbors (MNN) batch correction technique in the scran 508 
package was utilized, grouping cells by their chip and using the expression of genes 509 
with positive biological components (see Supplementary Methods for details). This 510 
produced a matrix of corrected low-dimensional component coordinates (d = 50) for 511 
each cell, which was used as input for downstream analyses. Entropy of cell expression 512 
before and after batch correction was assessed in R using the method described by Azizi 513 
et al(13) (Supplementary Fig. 1B; Supplementary Methods). 514 
 515 
Clustering and annotation 516 
Unsupervised clustering was performed with the PhenoGraph algorithm(48), using the 517 
first 10 MNN-corrected components as input. Clusters from PhenoGraph were manually 518 
assigned to a cell type by comparing the mean expression of known markers across cells 519 
in a cluster (see Supplementary Methods for details). For visualization purposes, tSNE 520 
transformation was performed with the scater package using the first 10 MNN-corrected 521 
components as input. All differential expression results were generated using the 522 
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findMarkers function of the scran package, which performs gene-wise t-tests between 523 
pairs of clusters, and adjusts for multiple testing with the Benjamini-Hochberg method. 524 
Diffusion map analysis(25) was performed using the algorithm implemented by the 525 
scater package (Supplementary Methods). 526 
 527 
Multi-color IHC on TMA, scanning and image analysis  528 
TMA slides were deparaffinized and incubated with each marker of interest (MHC class 529 
II, FOXP3, CD8, LAG3, CD4, CD30), followed by detection using Mach2 HRP and 530 
visualization using Opal fluorophores (Supplementary Table 4; see Supplementary 531 
Methods for details). Nuclei were visualized with DAPI staining. TMA slides were 532 
scanned using the Vectra multispectral imaging system (PerkinElmer, USA) following 533 
manufacturer’s instructions to generate .im3 image cubes for downstream analysis. To 534 
analyze the spectra for all fluorophores included, inForm image analysis software 535 
(v2.4.4; PerkinElmer, USA) was used. Cells were first classified into tissue categories 536 












 areas 537 




 regions 538 
were considered to be HRS-surrounding regions. Cells were then phenotyped as 539 
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positive or negative for each of the six markers (MHC class II, FOXP3, CD8, LAG3, 540 
CD4, CD30). Data were merged in R by X-Y coordinates so that each cell could be 541 
assessed for all markers simultaneously. Nearest neighbor analysis was performed with 542 
the spatstat R package (v1.58-2). 543 
 544 
Imaging mass cytometry (IMC) 545 
IMC was performed on a 5m section of the same TMA described above. The section 546 
was baked at 60°C for 90 min on a hot plate, de-waxed for 20 min in xylene and 547 
rehydrated in a graded series of alcohol (100%, 95%, 80% and 70%) for 5 min each. 548 
Heat-induced antigen retrieval was conducted on a hot plate at 95°C in Tris-EDTA 549 
buffer at pH 9 for 30 min. After blocking with 3% BSA in PBS for 45 min, the section 550 
was incubated overnight at 4C with a cocktail of 35 antibodies tagged with rare 551 
lanthanide isotopes (Supplementary Table 5). The section was counterstained the next 552 
day for 40 min with iridium (Ir) and 3 min with ruthenium tetroxide (RuO4) as 553 
described in Catena et al(49). Slides were imaged using the Fluidigm Hyperion IMC 554 
system with a 1µm laser ablation spot size and frequency of 100-200Hz. A tissue area 555 
of 1000µm
2
 per sample was ablated and imaged. Duplicate cores of the same samples 556 
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were ablated when morphologic heterogeneity was identified a priori on H&E. 557 
IMCTools (https://github.com/BodenmillerGroup/imctools) was used in conjunction 558 
with CellProfiler (v2.2.0) to segment images and identify cell objects (see 559 
Supplementary Methods for details).  560 
 561 
Cell lines 562 
The cHL cell lines KMH2, L428 and L-1236 were obtained from the German 563 
Collection of Microorganisms and Cell Cultures (DSMZ; http://www. dsmz.de/) 564 
between 2007 and 2010, and were used for experiments within 20 passages. Cultures 565 
were grown according to the standard conditions. Human DLBCL cell lines Karpas-422 566 
were purchased from DSMZ, and maintained in RPMI1640 (Life Technologies) 567 
containing 20% FBS. The cell line OCI-Ly1 was obtained from Dr. L. Staudt (NIH) in 568 
2009 and maintained in RPMI1640 (Life Technologies) containing 10% FBS. All cell 569 
lines were confirmed negative for Mycoplasma prior to culture using the Venor
TM
 GeM 570 
Mycoplasma Detection Kit, PCR-based (Sigma-Aldrich, MP0025). All cell lines were 571 
authenticated using short tandem repeat profiling. 572 
 573 
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 T lymphocytes from peripheral blood mononuclear cells 575 




 T cells 576 
were incubated in either supernatants from cHL cell lines (L-1236, L-428, KM-H2) or 577 
diffuse large B-cell lymphoma cell lines (OCI-Ly1 and Karpas-422) or culture medium. 578 
At the end of day 14, we washed and analyzed the T cells using flow cytometry for 579 








 T-cells by flow 580 
sorting on a FACS Fusion (BD Biosciences) using a 85μm nozzle. 581 
 582 
Flow cytometry 583 
To characterize T cells in vitro, we stained cells with a panel of antibodies including 584 
CD3, CD4, CD8 and LAG3 (see Supplementary Methods for details), and assessed 585 
them using flow cytometry (LSRFortessa or FACSymphony, BD, Franklin Lakes, NJ, 586 
USA). Flow cytometry data were analyzed using FlowJo software (v10.2; TreeStar, 587 
Ashland, OR, USA) (Supplementary Fig. 18). Statistical analyses were performed 588 
using GraphPad Prism Version 7 (GraphPad Software Inc., La Jolla, CA). 589 
 590 
In vitro suppression assay 591 
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To evaluate the suppressive activity of LAG3
+
 T cells, we stained CD4
+
 T cells 592 
(responder cells) with proliferation dye (VPD450; BD Biosciences or Cell Trace Violet 593 
Cell proliferation kit; Thermofisher) and activated them using soluble monoclonal 594 
antibodies to CD3 and CD28 in PRIME XV T cell CDM medium or CD3/CD28 Beads 595 




 T cells induced by cHL cell line 596 
supernatant transfer, or purified from cell suspensions of cHL clinical samples 597 
(suppressor cells) at a ratio of 1:1. We calculated the percentage of divided responder T 598 
cells by gating on CD4
+
 cells and T cell proliferation was determined based on 599 
proliferation dye dilution using flow cytometry (LSRFortessa and FACSymphony, BD, 600 
Franklin Lakes, NJ, USA).  601 
 602 
Cytokine and chemokine detection  603 
Cytokines and chemokines were measured by ELISA and custom Bio-Plex assays (see 604 
Supplementary Methods for details). 605 
 606 
Generation of CIITA knock-out cells 607 
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L-428 cell lines were transduced with lentivirus expressing guide sequence against 608 
CIITA to generate CIITA knock-out cells which abrogate the expression of MHC class II 609 
(Supplementary Fig. 19A-B; see Supplementary Methods for details). MHC class II 610 
expression was evaluated by staining the cells with FITC-HLA DR/DP/DQ antibody 611 
(1:100, BD Biosciences #555558) and analyzed using the BD LSRFortessa
TM
. 612 











 using the BD FACSAria
TM
 Fusion sorter. 614 
 615 










 T cells were co-cultured with either CIITA wild-type or 618 
CIITA KO L-428 at 2:1 ratio in a 96 well plate. 619 
 620 
Survival analysis 621 
Overall survival (OS, death from any cause), disease specific survival (DSS, the time 622 
from initial diagnosis to death from lymphoma or its treatment, with data for patients 623 
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who died of unrelated causes censored at the time of death) and post-BMT failure free 624 
survival (post-BMT-FFS, time from ASCT treatment to cHL progression, or death from 625 
cHL) were analyzed using the Kaplan-Meier method and results were compared using 626 
the log rank test. Univariate and multivariate Cox regression analyses were performed 627 
to assess the effects of prognostic factors. Survival analyses were performed in the R 628 
statistical environment (v3.5.2). 629 
 630 
Statistical results & visualization 631 
All t-tests reported are two-sided Student’s t-tests, and P-values < 0.05 were considered 632 
to be statistically significant. In all boxplots, boxes represent the interquartile range with 633 
a horizontal line indicating the median value. Whiskers extend to the farthest data point 634 
within a maximum of 1.5 × the interquartile range, and colored dots represent outliers. 635 
 636 
Data availability 637 
Single cell RNA-seq BAM files (generated with CellRanger v2.1.0) are deposited in 638 
EGA (EGAS00001004085) and are available by request. The figures associated with 639 
the above raw datasets are Fig. 1-4 and Supplementary Fig. 1-10. 640 
 641 
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Code availability 642 
Scripts used for data analysis are available upon request. 643 
  644 
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FIGURE LEGENDS 820 
Figure 1. Immune cell atlas of the Hodgkin lymphoma microenvironment at 821 
single-cell resolution. Cells from 22 cHL and 5 RLN cases were clustered using the 822 
PhenoGraph algorithm to identify groups of cells with similar expression patterns. A, 823 
Heatmap summarizing mean expression (normalized and log-transformed) of selected 824 
canonical markers in each cluster. Data has been scaled row-wise for visualization. The 825 
covariate bar on the left side indicates the component associated with each gene, and 826 
black boxes highlight prominent expression of known subtype genes. B, Single-cell 827 
expression of all cells from cHL and RLN in tSNE space (first two dimensions). Cells 828 
are colored according to PhenoGraph cluster. Subsets of cells from cHL and RLN 829 
samples are shown on the same coordinates below, respectively. C, Proportion of cells 830 
in each cluster originating from cHL and RLN samples. Clusters labeled in red highlight 831 
Treg clusters. Dashed white line represents the proportion of RLN cells in the total 832 
population. D, The proportion of cells assigned to a given immune cell type (as 833 
determined by cluster) was calculated for each sample. Boxplots summarize the 834 
distribution of the proportions for all samples, grouped by tissue type (cHL or RLN). 835 
P-values calculated using a t-test are shown above, and demonstrate a significant 836 
expansion in the proportion of Tregs present in cHL compared to RLN. E, Proportion of 837 
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 T cells (non-Treg) assigned to various subsets, calculated per sample and 838 
summarized with boxplots (see Methods for definition of subtypes). F-G, Proportion of 839 
immune cell types as in D-E, with samples separated according to EBV status (RLN not 840 
included). H, Proportion of immune cell types as in e, with samples separated according 841 
to histological subtype (RLN not included). 842 
 843 
Figure 2. Detailed characterization and co-expression patterns of regulatory T cells 844 
in the tumor microenvironment of classic Hodgkin Lymphoma. A, Violin plots 845 
showing distribution of expression values (normalized log-transformed) for genes 846 
associated with Treg function. Cells from three cluster types are included: CD4
+ 
T cells 847 
(non-Treg) (CD4-C1-Helper, CD4-C2-Helper and CD4-C3-Helper), LAG3
+
 Tregs 848 
(CD4-C5-Treg) and other Tregs (CD4-C4-Treg and CD4-C6-Treg). B, The number of 849 
individual cells co-expressing Treg markers LAG3 and FOXP3 in
 
all Treg clusters. C, 850 
Proportion of LAG3 and PDCD1 (PD-1) positive cells in each cluster. D, Proportion of 851 
LAG3 and PD-1 positive cells in all Tregs, CD4
+ 
T cells (non-Tregs), and all CD8
+
 T 852 
cells. E, Heatmap showing mean expression of inhibitory receptors for cluster subsets. 853 
Expression values have been scaled row-wise for visualization.  F, UpSet plot showing 854 
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co-expression patterns of inhibitory receptors (LAG3, PD-1, TIGIT, TIM3 and CTLA4) 855 
for individual cells in the LAG3
+
 Treg cluster. G, Cellular trajectories were inferred 856 
using diffusion map analysis of cells in all CD4
+
 T cell clusters (cHL cells only). 857 
Individual cells are shown in the first two resulting dimensions, and are colored 858 
according to cluster (LAG3
+
 Treg cluster is shown in bold). Axis labels indicate the 859 
signature most correlated with each dimension (see Methods). 860 
 861 
Figure 3. An immune suppressive microenvironment is characteristic of cHL and 862 
is associated with LAG3 positivity. A, Density plots showing the expression of 863 
suppressive cytokines for cells in the LAG3
+
 Treg cluster (CD4-C5-Treg). Cells are 864 
grouped by LAG3 positivity and P-values were calculated using t-tests. B, 865 
Representative flow cytometric analysis of CD25 and LAG3 expression on T cells 866 
isolated from PBMCs cultured with supernatant of cHL cell line, L-1236, or medium, 867 




 T cells cultured with 868 
supernatant of cHL cell lines (KM-H2, L-428 and L-1236), diffuse large B-cell 869 
lymphoma (DLBCL) cell lines (OCI-Ly1 and Karpas-422) or medium only. Data are 870 
shown as the mean±SEM (n = 3). *P ≤ 0.05; **P ≤ 0.01. D, The amount of cytokines 871 
and chemokines in the supernatant of cHL cell lines and DLBCL cell lines by Luminex 872 
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analysis. Data are shown as the mean±SEM (n = 3). E, The amount of cytokines and 873 









cells by Luminex analysis. Data are shown as the mean±SEM (n = 4). **P ≤ 0.01, *P ≤ 875 
0.0001. F, (left) A representative experiment showing proliferation of CD4
+
 responder 876 




 T cells (middle), or 877 




 T cells (top). (right) The percentage of 878 
proliferating CD4
+
 responder T cells in each co-culture condition, relative to the normal 879 
proliferation rate (alone). Data are shown as the mean±SEM (n = 4). *P ≤ 0.05.  880 
 881 
Figure 4. Spatial distribution of Hodgkin and Reed-Sternberg cells and LAG3
+
 T 882 
cells in cHL tumors. A, Representative LAG3 immunohistochemistry of cHL tumor 883 
biopsies and a reactive lymph node (×400, CHL03 and CHL05). B, Boxplot showing 884 
mean LAG3 expression of cells in the LAG3
+
 Treg cluster separated by MHC class II 885 
(MHC-II) status on HRS cells as determined by IHC (P = 0.0186; t-test). C, Volcano 886 
plot showing differentially expressed genes between cells in the LAG3
+
 Treg cluster 887 
originating from MHC-II positive or negative cases. The top 5 genes by absolute log 888 
fold-change in each direction are highlighted in red. The y-axis summarizes P-values 889 
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corrected for multiple testing using the Benjamini-Hochberg method. D, IHC staining 890 
for major immune cell markers in representative cases with either MHC-II positive HRS 891 











in the region surrounding 893 
CD30
+ 
cells (HRS) for each sample, separated by tissue type and MHC-II status on HRS 894 
cells (t-test; ns: P > 0.05, *: P ≤ 0.05, ***: P ≤ 0.001, ****: P ≤ 0.0001). F, Average 895 
nearest neighbor (NN) distance from an HRS cell (CD30
+









 cell (right) was calculated per sample, and separated by 897 
MHC-II status on HRS cells. P-values were calculated using t-tests. G, Multicolor IF 898 
staining (CHL03 and CHL05) for CD30 (yellow), MHC-II (green), and LAG3 899 




 T cells to the region surrounding HRS 900 
cells in cases with MHC-II negative HRS cells. 901 
 902 
Figure 5. Co-expression patterns and localization of immune cells according to 903 
HRS MHC-II status, using imaging mass cytometry. A, A representative case with 904 









 T cells (ii), with the LAG3
+
 cells rosetting the HRS cells (iii-iv). In 906 
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 T cells (vi), the latter surrounding HRS cells 908 
(vii-viii). B, Comparison of the proportion of LAG3
+
 cells by MHC-II status in a 909 
validation cohort.(6) P-values were calculated using t-tests. C, Comparison of the 910 
proportion of LAG3
+
 cells by EBV status in a validation cohort.(6) P-values were 911 
calculated using t-tests. 912 
 913 




 T cells. A, The expression of 914 
cytokines and chemokines on micro-dissected HRS cells from primary HL samples 915 
(separated by MHC class II status) and germinal center cells from reactive tonsil (GCB) 916 





 T cells after co-culture with supernatant of cHL cell lines 918 
(L-1236), medium with IL-6, or medium only. Data are shown as the mean ± SEM (n = 919 





 T cells (HLA-matched with L-428) after co-culture with either CIITA 921 
wild-type (Red) or CIITA KO L-428 (Blue). LAG3 expression on the T cells was 922 
significantly decreased after co-culture with MHC-II positive (CIITA KO) cells. (right) 923 
The percentage of highly-expressing LAG3
+ 
T cells after co-culture with L-428 CIITA 924 
variants (wild-type or knockout).
 
Data are shown as the mean ± SEM (n = 3). *: P ≤ 925 
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0.05. D, (left) A representative experiment showing proliferation of CD4
+
 T cells sorted 926 







T cells from cHL clinical samples (blue). (right) The percentage of proliferating 928 
cells in each condition are shown as the mean ± SEM (n = 4). *: P ≤ 0.05 (t-test). E, The 929 
expression of TNF in the populations described in D are shown as the mean ± SEM (n 930 
= 3). *: P ≤ 0.05 (t-test). 931 
 932 
Figure 7. A model of LAG3
+
 T cell and HRS cell interactions in classic Hodgkin 933 
lymphoma. 934 
Hypothetical model of LAG3
+
 T cell and HRS cell interactions in cHL. MHC-II 935 
negative HRS cells (Type 1) secrete cytokines that induce LAG3 in CD4
+





T cells surround HRS cells and secrete suppressive cytokines. MHC-II positive 937 
cells (Type 2) secrete a distinct set of cytokines that attract FOXP3
+
 and Th17 cells. 938 
 939 
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